In vitro Assays and analytics for Precision Medicine in hematological malignancies
Identification of Biomarkers To Predict Sensitivity Or Resistance To Treatments
Multiple Myeloma -The Complexity Of The Disease
Multiple Myeloma -The Complexity Of The Disease diag2tec-admin
About Multiple Myeloma (MM)
Multiple myeloma (MM) is a mostly incurable malignant disease of clonal plasma cells that accumulate in the bone marrow, leading to clinical signs and symptoms related to the displacement of normal hematopoiesis, development of bone disease, and production of monoclonal protein.
Treatment of MM consists of :
An induction phase with corticosteroid, proteasome inhibitor and immunomodulatory drug
A short term exposure to high dose of an alkylating agent
Autologous stem cell transplantation
Maintenance treatment (corticosteroid and immunomodulatory drug)
Cost of these myeloma treatments are among the highest in cancer : 80 to 100K€ / year / patient.
Patients invariably relapse after multiple lines of treatments. The overall survival of intensively-treated patients is of 6-7 years and the event-free survival of 3-4 years.
Epidemiology Informations :
Of blood cancer. The second most common hematologic malignancy after non-Hodgkin lymphoma.
of all cancer-related deaths in Western countries
News Cases/Year in the World. 25 000 new cases/year in United States (the same in Europe)
The complexity of the disease: functional studies are difficult in MM.